CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways
J Li, Q Huang, X Long, J Zhang, X Huang, J Aa… - Journal of …, 2015 - Elsevier
Background & Aims CD147 is a transmembrane glycoprotein which is highly expressed in
various human cancers including hepatocellular carcinoma (HCC). A drug Licartin
developed with 131 Iodine-labeled antibody against CD147 has been approved by the
Chinese Food and Drug Administration (FDA) and enters into clinical use for HCC treatment.
Increasing lines of evidence indicate that CD147 is implicated in the metabolism of cancer
cells, especially glycolysis. However, the molecular mechanism underlying the relationship …
various human cancers including hepatocellular carcinoma (HCC). A drug Licartin
developed with 131 Iodine-labeled antibody against CD147 has been approved by the
Chinese Food and Drug Administration (FDA) and enters into clinical use for HCC treatment.
Increasing lines of evidence indicate that CD147 is implicated in the metabolism of cancer
cells, especially glycolysis. However, the molecular mechanism underlying the relationship …
